Association of metabolic syndrome and hidradenitis suppurativa

JAMA Dermatology

Volumn 150, Issue 12, 2014, Pages 1273-1280

  Miller, Iben Marie ^a,b   Ellervik, Christina ^c   Vinding, Gabrielle Randskov ^a   Zarchi, Kian ^a   Ibler, Kristina Sophie ^a   Knudsen, Kim Mark ^d   Jemec, Gregor B E ^a,b  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NAESTVED HOSPITAL   (Denmark)

^d LEO PHARMA A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; ETHNICITY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; POPULATION RESEARCH; SMOKING; SUPPURATIVE HIDRADENITIS; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; AGED; BLOOD; DYSLIPIDEMIAS; HIDRADENITIS SUPPURATIVA; HYPERTRIGLYCERIDEMIA; MIDDLE AGED; OBESITY, ABDOMINAL; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; RISK ASSESSMENT; YOUNG ADULT;

EID: 84918541605     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.1165     Document Type: Article

References (32)

1. Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17(5):455-472
2. Jemec GBE. Clinical practice: Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164
3. Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol. 2010;90(3):264-268
4. Esmann S, Jemec GBE. Psychosocial impact of hidradenitis suppurativa: A qualitative study. Acta Derm Venereol. 2011;91(3):328-332
5. Jemec GBE, HeidenheimM, Nielsen NH. Hidradenitis suppurativa: Characteristics and consequences. Clin ExpDermatol. 1996;21(6):419-423
6. von derWerth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14(5):389-392.
7. Cosmatos I, Matcho A,Weinstein R, MontgomeryMO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412-419
8. Revuz JE, Canoui-Poitrine F,Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J AmAcad Dermatol. 2008;59(4):596-601
9. Vinding GR,Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: A population-based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170(4):884-889
10. Jemec GBE, HeidenheimM, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions.J AmAcadDermatol. 1996;35(2, pt 1):191-194
11. Vazquez BG, Alikhan A,Weaver AL,Wetter DA, DavisMD. Incidence of hidradenitis suppurativa and associated factors: A population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013; 133(1):97-103
12. Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7 (2):e31810. doi:10.1371/journal.pone.0031810
13. Gold DA, Reeder VJ, Mahan MG, et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J AmAcad Dermatol. 2014;70(4):699-703
14. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-Analysis of psoriasis, cardiovascular disease, and associated risk factors. J AmAcad Dermatol. 2013;69(6):1014-1024
15. Miller IM, Skaaby T, Ellervik C, Jemec GB. Quantifying cardiovascular disease risk factors in patients with psoriasis: Ameta-Analysis. Br J Dermatol. 2013;169(6):1180-1187
16. Miller IM, Jemec GBE.Maturation of an idea: A historical perspective on the association of psoriasis with themetabolic syndrome and cardiovascular disease [letter]. Arch Dermatol. 2012;148(1):112
17. Ferraz-Amaro I, González-Juanatey C, López-Mejias R, et al. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm. 2013; 2013:710928. doi:10.1155/2013/710928
18. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13-e18
19. Bergholdt HK, Bathum L, Kvetny J, et al. Study design, participation and characteristics of the Danish General Suburban Population Study. Dan Med J. 2013;60(9):A4693
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497
21. Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645
22. International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-1334
23. Institute for Rational Pharmacotherapy in Denmark. Guidelines on diabetes. Månedsbladet rationel farmakoterapi. 2006;8.www.irf.dk. Accessed May 21, 2014
24. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289(19):2560-2572
25. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211-213
26. Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506-1511
27. Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart Lung Circ. 2011;20(10):647-654
28. Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: A little help along the way. J Eur Acad Dermatol Venereol. 2013;27(9):1101-1108
29. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350
30. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207
31. Law MR, Morris JK,Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665
32. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: Influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118(20):2047-2056.